Docetaxel-PNP

DRUG3 trials

Sponsors

Samyang Biopharmaceuticals Corporation, Rahul Aggarwal

Conditions

Advanced Solid MalignanciesProstate CancerSolid Tumor

Phase 1

A Trial to Determine the Maximum Tolerated Dose and Evaluate the Safety and Pharmacokinetics of Docetaxel-PNP, Polymeric Nanoparticle Formulation of Docetaxel, in Subjects With Advanced Solid Malignancies

CompletedNCT01103791

Samyang Biopharmaceuticals CorporationAdvanced Solid Malignancies

Start: 2010-04-30End: 2012-04-30Updated: 2017-05-05

Pharmacokinetic Study of Docetaxel-PNP and Taxotere to Treat Patient With Advanced Solid Cancer

CompletedNCT02274610

Samyang Biopharmaceuticals CorporationSolid Tumor

Start: 2014-11-30End: 2015-12-31Updated: 2017-05-01

LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC

CompletedNCT02494921

Rahul AggarwalProstate Cancer

Start: 2015-11-20End: 2021-07-30Updated: 2022-08-31

Related Papers

A phase (Ph) 1b/2 study of ribociclib (R) in combination with docetaxel (D) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology2021-05-20

c15-149: A phase 1b study of the oral CDK4/6 inhibitor ribociclib in combination with docetaxel plus prednisone in metastatic castration resistant prostate cancer (mCRPC)—A prostate cancer clinical trials consortium study.

Journal of Clinical Oncology2018-05-202 citations